Skip to main content
. 2015 Jun 20;26(9):2347–2353. doi: 10.1007/s00198-015-3129-7

Fig. 1.

Fig. 1

Hazard ratio between treatments (teriparatide versus placebo) for morphometric vertebral fractures according to the 10-year probability of a major osteoporotic fracture calculated without inclusion of BMD (HR presented from 10th to 90th percentile). Note that greater HR implies lower efficacy